Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses (2019 - 2025)

China Pharma Holdings filings provide 7 years of Other Accumulated Expenses readings, the most recent being $1.9 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 20.91% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 20.91% increase, with the full-year FY2025 number at $1.9 million, up 20.91% from a year prior.
  • Other Accumulated Expenses hit $1.9 million in Q4 2025 for China Pharma Holdings, up from $1.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2021 to a low of $24000.0 in Q3 2024.
  • Median Other Accumulated Expenses over the past 5 years was $2.3 million (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 97.84% in 2024 and later skyrocketed 6614.61% in 2025.
  • China Pharma Holdings' Other Accumulated Expenses stood at $2.8 million in 2021, then decreased by 10.93% to $2.5 million in 2022, then crashed by 49.29% to $1.3 million in 2023, then rose by 26.44% to $1.6 million in 2024, then grew by 20.91% to $1.9 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $1.9 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.